WVE WAVE Life Sciences

Wave Life Sciences to Webcast Conference Call of First Quarter 2020 Financial Results on May 11, 2020

Wave Life Sciences to Webcast Conference Call of First Quarter 2020 Financial Results on May 11, 2020

CAMBRIDGE, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Monday, May 11, 2020, to discuss its first quarter 2020 financial results and provide a business update.

The webcast of the conference call may be accessed by visiting the “Events” section in the Investor Relations page of the Wave Life Sciences website at . The live teleconference may be accessed by dialing (866) 220-8068 (domestic) or (470) 495-9153 (international) and entering conference ID: 5669348. Following the conference call, an archived version of the call will be available on the website. 

About Wave Life Sciences

Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit and follow Wave on Twitter @WaveLifeSci.

Investor Contact:

Kate Rausch

617-949-4827

  

Media Contact:

Alicia Suter

617-949-4817

 

EN
29/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on WAVE Life Sciences

Wave Life Sciences Ltd: 1 director

A director at Wave Life Sciences Ltd bought 8,772,496 shares at 6.227USD and the significance rating of the trade was 83/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch